Hepatocyte

EQS-News: HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Wednesday, April 10, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • "The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans," emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Korro Reports Full Year 2023 Financial Results and Highlights Recent Progress

Retrieved on: 
Tuesday, March 26, 2024
Research, Piz, Adenosine deaminase, Half-life, Patient, Alnylam Pharmaceuticals, AAT, ADAR, Mouse, RNA, Chord, N-Acetylgalactosamine, Hepatocyte, Investment, Customization, Protein, Therapy, Research and development, Administration, Liver, Vaccine

KRRO-110 is the first RNA editing oligonucleotide product candidate from Korro’s platform called Oligonucleotide Promoted Editing of RNA (OPERA™).

Key Points: 
  • KRRO-110 is the first RNA editing oligonucleotide product candidate from Korro’s platform called Oligonucleotide Promoted Editing of RNA (OPERA™).
  • Using CHORDs, Korro achieved greater than 50% editing using GalNAc conjugates with subcutaneous administration to the liver in a preclinical mouse model.
  • Full Year 2023 Financial Results:
    Cash Position: Cash, cash equivalents and short-term investments were $166.1 million as of December 31, 2023, compared to $55.2 million as of December 31, 2022.
  • Net Loss: Korro’s net loss was $81.2 million for the year ended December 31, 2023, as compared to $58.0 million for the year ended December 31, 2022.

BioIVT to Host Symposium and Workshop in Brussels on Advanced In Vitro ADME Methodologies

Retrieved on: 
Tuesday, April 9, 2024
Molecule, AME Publishing Company, Development, Hepatocyte, Application, Travel, Running, Doctor of Philosophy, Senior, University of Oxford, ADME, Drug development, MPS

WESTBURY, N.Y., April 9, 2024 /PRNewswire/ -- BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host Small Molecules and Biologics: Advanced ADME Strategies & Techniques, a complimentary symposium and workshop on methodologies and techniques for in vitro ADME research. Hosted at BioIVT's office and laboratory in Brussels, this two-day event will take place from April 11-12 and feature speakers from industry, academia and BioIVT. The workshop will include workstations for attendees to see product demonstrations and talk to BioIVT product experts about how these products can be used in their research applications. Please visit BioIVT's website for registration and additional details here. 

Key Points: 
  • WESTBURY, N.Y., April 9, 2024 /PRNewswire/ -- BioIVT , a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will host Small Molecules and Biologics: Advanced ADME Strategies & Techniques , a complimentary symposium and workshop on methodologies and techniques for in vitro ADME research.
  • Hosted at BioIVT's office and laboratory in Brussels, this two-day event will take place from April 11-12 and feature speakers from industry, academia and BioIVT.
  • The workshop will include workstations for attendees to see product demonstrations and talk to BioIVT product experts about how these products can be used in their research applications.
  • In addition to being the largest supplier of products for in vitro ADME studies, the company also will discuss the preclinical research services it offers, including designing and implementing in vitro ADME-Tox programs.

HOOKIPA Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights

Retrieved on: 
Friday, March 22, 2024
SIV, Clinical trial, Hepatitis, Head, CPI, Serum, Hepatitis B, Partnership, HIV, Oncology, Gilead Sciences, Patient, Lung, Journal, Viral load, Pembrolizumab, HBV, Trial of the century, IND, Infection, Hepatocyte, Arenavirus, Antibody, Vaccination, Intellectual property, FDA, Liver, Animal, Pharmaceutical industry

“It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.

Key Points: 
  • “It was a defining year for HOOKIPA as we witnessed the powerful potential of our novel arenaviral immunotherapies in action.
  • Data was initially presented in May 2023 and additional patient data was provided in October at the European Society for Medical Oncology Congress 2023.
  • HOOKIPA expects to initiate a Phase 1 clinical study of HB-500 in people with HIV in the second quarter of 2024.
  • In June 2023, the Company completed a $50.0 million public offering of common stock and non-voting convertible preferred stock.

HepaRegeniX publishes data for its first-in-class MKK4 inhibitor HRX-215 for the treatment of acute and chronic liver diseases in Cell

Retrieved on: 
Thursday, March 14, 2024
Liver, Liver failure, DOI, Cell death, Regeneration, Clinical professor, Colorectal cancer, Transplant, Gesellschaft mit beschränkter Haftung, Hepatectomy, Risk, Patient, MKK4, Mayo Clinic, Manuscript, Liver transplantation, Teaching hospital, Human, MAP, Liver regeneration, Hepatocyte, PHLF, Regenerative medicine, Safety, Hepatology, Liver disease, Dietary supplement

HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).

Key Points: 
  • HRX-215 is a small molecule inhibitor of Mitogen-Activated Protein (MAP) Kinase Kinase 4 (MKK4).
  • “The positive results in terms of safety and tolerability confirm our intention to soon offer a drug that has the potential to revolutionize the treatment of severe liver diseases.
  • The data pave the way for further Phase II studies evaluating the efficacy of HRX-215 in humans,” emphasizes Dr. Wolfgang Albrecht, COO of HepaRegeniX.
  • Further, HRX-215 was also able to protect hepatocytes from cell death in a model for acute liver injury.

Induced Pluripotent Stem Cells Market Report, Featuring Historical Revenue Data for 2021 and 2022, Estimated Figures for 2023, and Compound Annual Growth Rates (CAGRs) through 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 12, 2024
Science, Stem Cells, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Cell, Stem cell, Fibroblast, B cell, Enzyme, Serum, Drug discovery, Row, Good manufacturing practice, Differentiable function, Neuron, GMP, Hepatocyte, Regenerative medicine, Medium (website), Antibody, Drug development, Geography, Astrocyte, IPSC, Endothelium

For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.

Key Points: 
  • For instance, product function-based market segments include molecular and cellular engineering, cellular reprogramming, cell culture, cell differentiation, and cell analysis.
  • An in-depth patent analysis and research funding analysis are also included to assess the overall direction of the iPSC market.
  • The induced pluripotent stem cell market has been analyzed for four main geographic regions: The U.S., Europe, Asia-Pacific, and the Rest of the World (RoW).
  • The report will provide details with respect to induced pluripotent stem cells.

Sirnaomics will Present its Innovative Dual-Targeted GalNAc muRNA Programs in 2024 OPT Conference

Retrieved on: 
Tuesday, March 12, 2024
Gene, Congress, Oligonucleotide, Patient, RNA, Messenger, N-Acetylgalactosamine, Hepatocyte, Therapy, Múrna, RNA interference, Liver

Based on Sirnaomics' continued progress in targeting single genes with GalAheadTM mxRNA, Company is now pioneering GalAheadTM muRNA, a proprietary RNAi-based platform that allows for simultaneous downregulating of multiple genes.

Key Points: 
  • Based on Sirnaomics' continued progress in targeting single genes with GalAheadTM mxRNA, Company is now pioneering GalAheadTM muRNA, a proprietary RNAi-based platform that allows for simultaneous downregulating of multiple genes.
  • GalAheadTM muRNA, alike mxRNA employs GalNAc ligands, a clinically validated concept for RNAi trigger delivery to liver hepatocytes providing subsequent treatment of liver associated diseases.
  • The cleavage points allow for the muRNA after cellular delivery to break into two individual RNAi-triggers in the endo-lysosomal pathway.
  • In a different scenario, muRNA can simultaneously address two or more non-associated indications where patient populations have a considerable overlap.

Generation Bio Reports Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Wednesday, March 6, 2024
Therapy, Research, Haemophilia, DSM-IV codes, HSC, Health, Thalassemia, Sickle cell disease, G&A, Hepatocyte, DNA, Mouse, Vaccine

CAMBRIDGE, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and fourth quarter and full year 2023 financial results.

Key Points: 
  • (Nasdaq:GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, reported business highlights and fourth quarter and full year 2023 financial results.
  • “Late last year we announced important advances in our cell-targeted lipid nanoparticle and immune-quiet DNA platforms that we are now translating to our portfolio strategy,” said Geoff McDonough, M.D., chief executive officer of Generation Bio.
  • We are also continuing to optimize iqDNA to progress our hemophilia A program and to explore therapeutic applications in cell types beyond hepatocytes.
  • In 2024, the company intends to optimize iqDNA for application in hepatocytes and T cells with a focus on improving potency.

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Retrieved on: 
Wednesday, January 3, 2024
RNA, RNA interference, Liver, Partnership, NASH, Boehringer Ingelheim, Cirrhosis, Hepatocyte, Small RNA, Boehringer, Research, Messenger, USD, DSM-IV codes, CRM, Liver failure, Liver cancer, Patient, Therapy, Senior, Pharmaceutical industry

INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Key Points: 
  • INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
  • More than 440 million people worldwide are estimated to live with NASH, an inflammatory liver disease that is caused by accumulation of fat in the liver.
  • Over time, NASH causes scar tissue formation, which in many cases leads to liver cirrhosis and related serious complications, including liver failure or liver cancer.
  • We are very pleased about the opportunity to work with Boehringer Ingelheim to develop new solutions for people living with NASH."

Ribo partners with Boehringer Ingelheim to develop new treatments for people with liver diseases

Retrieved on: 
Wednesday, January 3, 2024
RNA, RNA interference, Liver, Partnership, NASH, Boehringer Ingelheim, Cirrhosis, Hepatocyte, Small RNA, Boehringer, Research, Messenger, USD, DSM-IV codes, CRM, Liver failure, Liver cancer, Patient, Therapy, Senior, Pharmaceutical industry

INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).

Key Points: 
  • INGELHEIM, Germany, MÖLNDAL, Sweden and KUNSHAN, China, Jan. 3, 2024 /PRNewswire/ -- Suzhou Ribo Life Science Co., Ltd. and Ribocure AB (Ribo) today announced a collaboration with Boehringer Ingelheim to develop novel treatments for nonalcoholic or metabolic dysfunction-associated steatohepatitis (NASH/MASH).
  • More than 440 million people worldwide are estimated to live with NASH, an inflammatory liver disease that is caused by accumulation of fat in the liver.
  • Over time, NASH causes scar tissue formation, which in many cases leads to liver cirrhosis and related serious complications, including liver failure or liver cancer.
  • We are very pleased about the opportunity to work with Boehringer Ingelheim to develop new solutions for people living with NASH."